scholarly journals Overall survival and second primary malignancies in men with metastatic prostate cancer

PLoS ONE ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. e0227552 ◽  
Author(s):  
Juha Mehtälä ◽  
Jihong Zong ◽  
Zdravko Vassilev ◽  
Gunnar Brobert ◽  
Montse Soriano Gabarró ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Metastatic Prostate Cancer ◽  
Second Primary ◽  
Second Primary Malignancies

Prognostic Impact of Synchronous Second Primary Malignancies on the Overall Survival of Patients with Metastatic Prostate Cancer

2015 ◽  
Vol 193 (4) ◽  
pp. 1239-1244 ◽  
Author(s):  
Kyo Chul Koo ◽  
Hanna Yoo ◽  
Ki Hong Kim ◽  
Sang Un Park ◽  
Kyung Seok Han ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Metastatic Prostate Cancer ◽  
Second Primary ◽  
Prognostic Impact ◽  
Second Primary Malignancies

scholarly journals Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yi Liu ◽  
Peipei Zhang ◽  
Yinghao Zhang ◽  
Lichuan Zheng ◽  
Wenbo Xu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Cox Regression ◽  
Characteristic Curve ◽  
Clinical Information ◽  
Population Based ◽  
Second Primary ◽  
Cox Regression Analysis ◽  
Validation Set ◽  
Second Primary Malignancies

AbstractProstate cancer (PCa) is the most prevalent cancer among males and the survival period of PCa has been significantly extended. However, the probability of suffering from second primary malignancies (SPMs) has also increased. Therefore, we downloaded SPM samples from the SEER database and then retrospectively analyzed the general characteristics of 34,891 PCa patients diagnosed between 2000 and 2016. After excluding cases with unknown clinical information, 2203 patients were used to construct and validate the overall survival (OS) nomogram of SPM patients after PCa. We found that approximately 3.69% of PCa patients were subsequently diagnosed with SPMs. In addition, the three most prevalent sites of SPM were respiratory and intrathoracic organs, skin, and hematopoietic system. The top three histological types of SPMs were squamous cell carcinoma, adenoma and adenocarcinoma, nevi and melanoma. Through univariate and multivariate Cox regression analysis, we found that the site of SPM, age, TNM stage, SPM surgery history, and PCa stage were associated with the OS of SPM. By virtue of these factors, we constructed a nomogram to predict the OS of SPM. The C-index in the training set and validation set were 0.824 (95CI, 0.806–0.842) and 0.862 (95CI, 0.840–0.884), respectively. Furthermore, we plotted the receiver operating characteristic curve (ROC) and the area under curve (AUC) which showed that our model performed well in assessing the 3-year (0.861 and 0.887) and 5-year (0.837 and 0.842) OS of SPMs in the training and validation set. In summary, we investigated the general characteristics of SPMs and constructed a nomogram to predict the prognosis of SPM following PCa.

SECOND PRIMARY MALIGNANCIES IN T1-3N0 PROSTATE CANCER PATIENTS TREATED WITH RADIATION THERAPY WITH 10-YEAR FOLLOWUP

1998 ◽  
Vol 159 (3) ◽  
pp. 946-949 ◽  
Author(s):  
PETER A.S. JOHNSTONE ◽  
CURT R. POWELL ◽  
ROBERT RIFFENBURGH ◽  
DAVID C. ROHDE ◽  
CHRISTOPHER J. KANE
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Second Primary ◽  
Second Primary Malignancies

The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies

2018 ◽  
Vol 36 (11) ◽  
pp. 500.e11-500.e19 ◽  
Author(s):  
Ross E. Krasnow ◽  
Dayron Rodríguez ◽  
Ramzy T. Nagle ◽  
Matthew Mossanen ◽  
Adam S. Kibel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Localized Prostate Cancer ◽  
Second Primary ◽  
Second Primary Malignancies ◽  
The Impact

scholarly journals Local and systemic morbidities of de novo metastatic prostate cancer in Singapore: insight from 685 consecutive patients from a large prospective Uro-oncology registry

BMJ Open ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. e034331 ◽  
Author(s):  
Yu Guang Tan ◽  
Leonard Pang ◽  
Farhan Khalid ◽  
Randy Poon ◽  
Hong Hong Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Metastatic Prostate Cancer ◽  
Group Performance ◽  
De Novo ◽  
Eastern Cooperative Oncology Group ◽  
Specific Antigen ◽  
High Volume ◽  
Secondary Outcome ◽  
Systemic Complications

ObjectiveTo evaluate the incidence and management of local and systemic complications afflicting patients with de novo metastatic prostate cancer (mPCa) in Singapore.DesignRetrospective analysis of a large prospective Uro-oncology registry of mPCa.SettingThis study is carried out in a tertiary hospital in Singapore.ParticipantsWe reviewed our institution’s prospectively maintained database of 685 patients with mPCa over a 20-year period (1995–2014). Patients with non-mPCa or those progressed to metastatic disease after previous curative local treatments were excluded.Primary and secondary outcome measuresThe primary outcome was to evaluate the systemic and local morbidity rates associated with mPCa. Local complication was defined as the need for palliative procedures to relieve urinary obstruction, worsening renal function or refractory haematuria, while systemic complication was related to radiographic evidence of skeletal-related pathological fractures. Secondary outcomes analysed were the management and overall survival patterns over 20 years.Results237 (34.6%) patients required local palliative treatments. 88 (12.8%) patients presented with acute urinary retention, 23 patients (9.7%) required repetitive local palliative treatments. On multivariate analyses, prostate-specific antigen >100 (p=0.02) and prostate volume >50 g (p=0.03) were independent prognostic factors for significant obstruction requiring palliative procedures. 118 (17.2%) patients developed skeletal fractures, with poor Eastern Cooperative Oncology Group Performance (ECOG) status (p=0.01) and high volume bone metastasis (p<0.01) independently predictive of skeletal fractures. Altogether, 653 (95.3%) patients received androgen deprivation therapy (ADT), with the median time to castrate resistance of 21.4 months (IQR 7–27). The median overall survival was 45 months (IQR 20–63), with prostate cancer mortality of 81.4%. Improved overall survival was observed from 41.6 months (1995–1999) to 47.8 months (2010–2014) (p<0.01).ConclusionMorbidities and complications arising from mPCa are more common and debilitating than we thought, often requiring immediate palliative treatments, while many necessitate repeated interventions with progression.

scholarly journals Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Catherine W. Saltus ◽  
Zdravko P. Vassilev ◽  
Jihong Zong ◽  
Brian Calingaert ◽  
Elizabeth B. Andrews ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Cohort Study ◽  
Incidence Rate ◽  
Retrospective Cohort ◽  
Population Based ◽  
Second Primary ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Second Primary Malignancies

Background. New therapies for castration-resistant prostate cancer (CRPC) may be associated with increased risk of second primary malignancies (SPM). We therefore estimated the population-based incidence of SPM among patients with CRPC in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. We also estimated the proportion of men with CRPC with bone metastases and overall survival. Methods. We conducted a retrospective cohort study of United States (US) men aged ≥ 65 years with CRPC. Cohort entry was from January 1, 2000, to December 31, 2011, with follow-up through December 31, 2013. Castration resistance was defined by treatment with second-line systemic therapy (after surgical or medical castration). SPM were diagnoses of primary cancers (other than prostate) in SEER or Medicare data. Results. Altogether 2,234 patients met eligibility criteria. Most (1,887; 84.5%) had evidence of bone metastases in Medicare claims. SPM occurred in 172 patients (incidence rate 5.9 per 100 person-years; 95% confidence interval [CI], 5.0-6.8; standardized incidence ratio = 3.1, 95% CI, 2.8-3.6, based on SEER incidence rate of all malignancies except prostate cancer among men aged ≥ 65 years). The most common SPM were lung/bronchus (n = 29, 16.9%), urinary bladder (n = 22, 12.8%), and colon/rectum (n = 21, 12.2%). Median survival was 1.2 years (95% CI, 1.1-1.3); 5-year survival was 9% (95% CI, 7-11%). Conclusions. This study provides the first estimate of SPM risk in older men with CRPC in the US. The incidence rate is approximately threefold higher than the population-based cancer incidence among men without prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document